Xvivo Perfusion (XVIVO) Stock Overview
A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
XVIVO Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Xvivo Perfusion AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 277.60 |
| 52 Week High | SEK 321.00 |
| 52 Week Low | SEK 160.00 |
| Beta | 1.44 |
| 1 Month Change | -1.14% |
| 3 Month Change | 52.44% |
| 1 Year Change | -12.70% |
| 3 Year Change | 3.01% |
| 5 Year Change | -24.87% |
| Change since IPO | 1,361.05% |
Recent News & Updates
Narrative Update • Jun 01
XVIVO: Positive Heart Trial Outcomes Will Support Stronger Long Term Outlook
Analysts have raised their price target on Xvivo Perfusion from SEK245 to SEK320, citing updated assumptions that include a revised revenue growth outlook, a slightly lower discount rate, a modestly reduced profit margin, and a higher future P/E multiple. What's in the News Preliminary late breaking data from the PRESERVE Trial indicate that hypothermic oxygenated perfusion using XVIVO Heart Assist Transport met its pre specified primary safety and efficacy endpoints in preserving and transporting extended criteria donor hearts, with plans to submit the results to the U.S. Food and Drug Administration as part of a Pre Market Approval process later in the year (Key Developments).
Narrative Update • May 10
XVIVO: Heart Trial Success Will Support Long Term Upside Potential
Analysts have revised their price target for Xvivo Perfusion from SEK 313.40 to SEK 337.00. This reflects updated assumptions on revenue growth, profit margins, discount rate and future P/E multiples.Recent updates
Narrative Update • Jun 01
XVIVO: Positive Heart Trial Outcomes Will Support Stronger Long Term Outlook
Analysts have raised their price target on Xvivo Perfusion from SEK245 to SEK320, citing updated assumptions that include a revised revenue growth outlook, a slightly lower discount rate, a modestly reduced profit margin, and a higher future P/E multiple. What's in the News Preliminary late breaking data from the PRESERVE Trial indicate that hypothermic oxygenated perfusion using XVIVO Heart Assist Transport met its pre specified primary safety and efficacy endpoints in preserving and transporting extended criteria donor hearts, with plans to submit the results to the U.S. Food and Drug Administration as part of a Pre Market Approval process later in the year (Key Developments).Narrative Update • May 10
XVIVO: Heart Trial Success Will Support Long Term Upside Potential
Analysts have revised their price target for Xvivo Perfusion from SEK 313.40 to SEK 337.00. This reflects updated assumptions on revenue growth, profit margins, discount rate and future P/E multiples.Narrative Update • Apr 22
XVIVO: Heart Trial Outcomes Will Support Balanced Long Term Risk Reward Profile
Analysts now set their price target for Xvivo Perfusion at SEK 313.40, compared with the previous SEK 301.00. This reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E multiples.Narrative Update • Apr 07
XVIVO: Stable Return Assumptions And Margins Will Support Balanced Future Outlook
Analysts have maintained their SEK245.0 price target for Xvivo Perfusion, citing slightly revised assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio, which together support a stable valuation view. Valuation Changes Fair Value: SEK245 has been reaffirmed, with only a minor presentational change from SEK245 to SEK245.0. Discount Rate: Adjusted slightly higher from 5.95% to 6.01%, reflecting a modest change in the required return assumption.Narrative Update • Mar 24
XVIVO: Higher Margins And Discount Assumptions Will Support Future Upside Potential
Analysts have modestly reduced their price target for Xvivo Perfusion to SEK245. This reflects slightly higher discount rate assumptions alongside small adjustments to revenue growth, profit margin, and future P/E expectations.Narrative Update • Mar 10
XVIVO: Higher Growth Assumptions Will Support Continued Bullish Repricing
Analysts now set their price target for Xvivo Perfusion at SEK301.0, compared with the prior SEK316.6, reflecting updated assumptions around slightly higher revenue growth, a lower profit margin, a higher discount rate, and a modestly higher future P/E multiple. Valuation Changes Fair Value: SEK316.6 has been revised to SEK301.0, a modest reduction in the estimated valuation level.Narrative Update • Feb 23
XVIVO: Higher Margins And Revenue Assumptions Will Support Future Upside Potential
Analysts now estimate Xvivo Perfusion's fair value at SEK245 per share, up from SEK215. This reflects updated assumptions for revenue growth, profit margins and a lower future P/E multiple in their models.
Narrative Update • Feb 09
XVIVO: Higher Required Returns Will Still Support Attractive Upside Potential
Analysts have reduced their fair value estimate for Xvivo Perfusion to $385 from $425, citing slightly higher discount rate assumptions, more cautious views on revenue growth and profit margins, and a higher applied future P/E multiple. Valuation Changes Fair Value: Reduced from SEK 425 to SEK 385, reflecting a more conservative overall valuation input set.Analysis Article • Jan 30
Xvivo Perfusion AB (publ) Just Beat EPS By 134%: Here's What Analysts Think Will Happen Next
It's been a good week for Xvivo Perfusion AB (publ) ( STO:XVIVO ) shareholders, because the company has just released...Narrative Update • Jan 26
XVIVO: Slight Assumption Tweaks Will Support Continued Bullish Repricing
Analysts have trimmed their price target on Xvivo Perfusion by about $1 to reflect slightly adjusted assumptions around fair value, the discount rate, revenue growth, profit margin and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from SEK 317.6 to SEK 316.6 per share.Narrative Update • Jan 11
XVIVO: Recent Upgrade And SEK 225 Level Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for Xvivo Perfusion by about SEK 2 to SEK 317.6, reflecting slightly adjusted assumptions on growth and margins. They also point to the recent upgrade to Buy from Hold and a SEK 225 target as support for a more constructive view on the shares.Narrative Update • Dec 17
XVIVO: Upgrade And SEK 225 Price Signal Will Drive Bullish Re-Rating
Analysts have raised their price target on Xvivo Perfusion to SEK 225, reflecting increased confidence in the company’s growth and profitability profile following the recent upgrade to Buy and the reaffirmation of robust long term revenue and margin assumptions. Analyst Commentary Bullish analysts highlight that the upgraded recommendation and SEK 225 price target signal rising conviction in Xvivo Perfusion’s medium term growth trajectory and execution capabilities.Narrative Update • Dec 03
XVIVO: Upgraded To Buy As Execution Phase Will Unlock Upside Potential
Analysts have modestly raised their price target on Xvivo Perfusion to SEK 225 from SEK 319.6, reflecting increased confidence in the company’s long term growth potential following recent research upgrades. Analyst Commentary Bullish analysts view the recent upgrade and revised target as a signal that Xvivo Perfusion is entering a more robust execution phase, with clearer line of sight to its long term growth ambitions.Narrative Update • Nov 19
XVIVO: Upgraded to Buy on Expectations of Sustained Margin Improvement
Narrative Update on Xvivo Perfusion Analysts have raised their price target for Xvivo Perfusion to SEK 225, citing improved profit margins and a more favorable valuation outlook. Analyst Commentary Recent analyst updates have highlighted both optimistic and cautious perspectives on Xvivo Perfusion in light of the company's performance and valuation adjustments.Narrative Update • Nov 05
XVIVO: Recent Upgrade Signals Improving Prospects Amid Rising Confidence
Narrative Update on Xvivo Perfusion Analysts have lowered their fair value estimate for Xvivo Perfusion from SEK 322.6 to SEK 319.6. This change reflects revised growth projections and recent research that supports an improving outlook despite the modest reduction. Analyst Commentary Analyst commentary on Xvivo Perfusion reveals diverging views regarding the company's near-term prospects, execution, and valuation trajectory.Narrative Update • Oct 22
Analysts Keep Xvivo Perfusion Fair Value Steady as Growth and Profit Estimates Slightly Ease
Analysts have modestly adjusted their price target for Xvivo Perfusion, maintaining the fair value estimate at SEK 322.6 per share. This reflects minor updates in projected growth and profitability metrics.Narrative Update • Oct 08
DELIVER IDE Approvals And US Trials Will Unlock New Markets
Narrative Update on Xvivo Perfusion Analysts have lowered their fair value estimate for Xvivo Perfusion to SEK 322.6 from SEK 345.6. The updated price target reflects revised assumptions on profit margins and revenue growth, as well as increased confidence signaled by a recent upgrade to Buy. Analyst Commentary Analysts have provided updated perspectives following the recent price target adjustment and rating upgrade for Xvivo Perfusion.Analysis Article • Jul 17
These Analysts Just Made A Massive Downgrade To Their Xvivo Perfusion AB (publ) (STO:XVIVO) EPS Forecasts
The latest analyst coverage could presage a bad day for Xvivo Perfusion AB (publ) ( STO:XVIVO ), with the analysts...Analysis Article • Jul 14
Earnings Miss: Xvivo Perfusion AB (publ) Missed EPS And Analysts Are Revising Their Forecasts
There's been a major selloff in Xvivo Perfusion AB (publ) ( STO:XVIVO ) shares in the week since it released its...Analysis Article • Jul 12
Xvivo Perfusion AB (publ)'s (STO:XVIVO) 37% Cheaper Price Remains In Tune With Earnings
Xvivo Perfusion AB (publ) ( STO:XVIVO ) shares have had a horrible month, losing 37% after a relatively good period...Analysis Article • Jun 20
Xvivo Perfusion (STO:XVIVO) Is Doing The Right Things To Multiply Its Share Price
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Analysis Article • Apr 03
Xvivo Perfusion AB (publ)'s (STO:XVIVO) Intrinsic Value Is Potentially 36% Above Its Share Price
Key Insights Xvivo Perfusion's estimated fair value is kr384 based on 2 Stage Free Cash Flow to Equity Xvivo...
New Narrative • Mar 13
Success Of US Heart Trial Will Strengthen Position In Heart Transplantation Market
Strategic acquisitions and production scaling are anticipated to enhance sales growth, operational efficiency, and improve gross margin profitability.Analysis Article • Mar 10
Market Participants Recognise Xvivo Perfusion AB (publ)'s (STO:XVIVO) Earnings
With a price-to-earnings (or "P/E") ratio of 75x Xvivo Perfusion AB (publ) ( STO:XVIVO ) may be sending very bearish...Analysis Article • Jan 31
Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders of Xvivo Perfusion AB (publ) ( STO:XVIVO ) will be pleased this week, given that the stock price is up 11...Analysis Article • Jan 30
Xvivo Perfusion (STO:XVIVO) Is Experiencing Growth In Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Analysis Article • Dec 06
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 43% Undervaluation?
Key Insights Xvivo Perfusion's estimated fair value is kr801 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • Nov 04
Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News
Even though Xvivo Perfusion AB (publ) ( STO:XVIVO ) posted strong earnings recently, the stock hasn't reacted in a...Analysis Article • Oct 27
Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Last week, you might have seen that Xvivo Perfusion AB (publ) ( STO:XVIVO ) released its quarterly result to the...Analysis Article • Oct 25
With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For
With a price-to-sales (or "P/S") ratio of 19.9x Xvivo Perfusion AB (publ) ( STO:XVIVO ) may be sending very bearish...Analysis Article • Aug 03
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?
Key Insights Xvivo Perfusion's estimated fair value is kr820 based on 2 Stage Free Cash Flow to Equity Xvivo Perfusion...Analysis Article • Apr 25
Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
The Xvivo Perfusion AB (publ) ( STO:XVIVO ) share price has done very well over the last month, posting an excellent...Analysis Article • Apr 11
There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...Analysis Article • Feb 05
Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates
Today is shaping up negative for Xvivo Perfusion AB (publ) ( STO:XVIVO ) shareholders, with the analysts delivering a...Analysis Article • Feb 01
We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings
Despite announcing strong earnings, Xvivo Perfusion AB (publ)'s ( STO:XVIVO ) stock was sluggish. Our analysis...Analysis Article • Jan 28
Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Last week, you might have seen that Xvivo Perfusion AB (publ) ( STO:XVIVO ) released its annual result to the market...Shareholder Returns
| XVIVO | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 0.3% | 0.7% | 0.03% |
| 1Y | -12.7% | -9.5% | 11.2% |
Return vs Industry: XVIVO underperformed the Swedish Medical Equipment industry which returned -9.5% over the past year.
Return vs Market: XVIVO underperformed the Swedish Market which returned 11.2% over the past year.
Price Volatility
| XVIVO volatility | |
|---|---|
| XVIVO Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 14.0% |
| 10% least volatile stocks in SE Market | 3.7% |
Stable Share Price: XVIVO has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: XVIVO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 199 | Christoffer Rosenblad | www.xvivogroup.com |
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient.
Xvivo Perfusion AB (publ) Fundamentals Summary
| XVIVO fundamental statistics | |
|---|---|
| Market cap | SEK 8.85b |
| Earnings (TTM) | SEK 73.86m |
| Revenue (TTM) | SEK 834.53m |
118.4x
P/E Ratio10.5x
P/S RatioIs XVIVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XVIVO income statement (TTM) | |
|---|---|
| Revenue | SEK 834.53m |
| Cost of Revenue | SEK 224.38m |
| Gross Profit | SEK 610.16m |
| Other Expenses | SEK 536.29m |
| Earnings | SEK 73.86m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 13, 2026
| Earnings per share (EPS) | 2.34 |
| Gross Margin | 73.11% |
| Net Profit Margin | 8.85% |
| Debt/Equity Ratio | 0% |
How did XVIVO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 20:03 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xvivo Perfusion AB (publ) is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Simon Larsson | Danske Bank |
| Jonatan Andersson | DNB Carnegie |